NCT04261660

Brief Summary

Assessing the relationship between the VEGF levels in blood and the IVF protocol

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2020

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 6, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 10, 2020

Completed
20 days until next milestone

Study Start

First participant enrolled

March 1, 2020

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2021

Completed
Last Updated

February 10, 2020

Status Verified

February 1, 2020

Enrollment Period

1 year

First QC Date

February 6, 2020

Last Update Submit

February 7, 2020

Conditions

Reproductive Techniques

Outcome Measures

Primary Outcomes (1)

  • vascular endothelial growth factor LEVELS

    levels of vascular endothelial growth factor in blood

    5 days

Study Arms (3)

fresh

NO INTERVENTION

Other: NO intervention

Frozen embro transfer natural

NO INTERVENTION

Other: NO intervention

Frozen embro transfer hormonal

NO INTERVENTION

Other: NO intervention

Interventions

NO interventionOTHER

NO INTERVENTION

Frozen embro transfer hormonalFrozen embro transfer naturalfresh

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsPATIENTS UNDERGOING IN VITRO FERTLIZATION
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Female patients undergoing ovum pickup and embryo transfer as part of assited reproductive technologies

You may qualify if:

  • Patients undergoing IVF -

You may not qualify if:

  • Women with any malignancy
  • Patients request to be withdrawn

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITHOUT DNA

Patients serum

Study Officials

  • Ido Feferkorn, MD

    Carmel Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

ido Fefekorn, MD

CONTACT

+972-54-3537401idofe@clalit.org.il

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Physician

Study Record Dates

First Submitted

February 6, 2020

First Posted

February 10, 2020

Study Start

March 1, 2020

Primary Completion

March 1, 2021

Study Completion

April 1, 2021

Last Updated

February 10, 2020

Record last verified: 2020-02

Data Sharing

IPD Sharing
Will not share